Skip to main content
. 2024 Feb 6;15:974. doi: 10.1038/s41467-024-44905-z

Fig. 1. Manufacture and characterization of agenT-797.

Fig. 1

agenT-797 is manufactured by isolation of iNKT cells from peripheral blood mononuclear cells of healthy donors, iNKT-specific stimulation and expansion in vitro. A Levels of circulating iNKT cells were measured in PBMCs of 15 healthy donors and manufacturing cut-off was set at 0.05% of CD3+ lymphocytes (filled, above cut-off, open, below cut-off). B From selected donors, iNKT cells were purified and cells expanded using MiNK Therapeutics’ manufacturing protocol. At the end of manufacturing, purity of culture measured >99%. C Cytokines that were produced during expansion of iNKT cells were measured from supernatant cultures at the end of manufacturing. Both Th1 (IFN-γ, GM-CSF, TNF-α) and Th2 (IL-4, IL-5, IL-13) cytokines were produced. Data from two separate manufacturing runs using starting material from different donors (bars represent mean). agenT-797 iNKT cell products were subjected to flow cytometric analysis of intracellular cytokines (D) and surface markers (E) as shown. The CD4+ and negative iNKT populations expressed distinct levels of each marker. Data representative of agenT-797 batches manufactured to date (>10).